<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203111</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_R_05048</org_study_id>
    <secondary_id>U1111-1116-3517</secondary_id>
    <nct_id>NCT01203111</nct_id>
  </id_info>
  <brief_title>Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs</brief_title>
  <acronym>CHANGING</acronym>
  <official_title>Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin&#xD;
      glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week&#xD;
      24 (visit 10).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. Percentage of patients with HbA1c &lt; 7% at week 24.&#xD;
&#xD;
        2. Percentage of patients with HbA1c &lt; 7% and no symptomatic nocturnal hypoglycemia event&#xD;
           at week 24.&#xD;
&#xD;
        3. Fasting Plasma Glucose (FPG) and 7-point Self Monitoring of Blood Glucose (SMBG) at week&#xD;
           0, week 12 and week 24.&#xD;
&#xD;
        4. Doses of insulin glargine and insulin glulisine: the daily dose (U) and the daily dose /&#xD;
           kg (U/kg) will be calculated at week 24.&#xD;
&#xD;
        5. Systolic and diastolic blood pressure, heart rate, weight change will be measured at&#xD;
           week 0, week 12 and week 24.&#xD;
&#xD;
        6. Number of patients suffering hypoglycemias (asymptomatic, symptomatic, nocturnal&#xD;
           symptomatic, severe and nocturnal severe) will be evaluated during the treatment period.&#xD;
           7-Adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided in 3 periods:&#xD;
&#xD;
        1. a 2-week run-in period,&#xD;
&#xD;
        2. a 12-week treatment period 1&#xD;
&#xD;
        3. a 12-week treatment period 2 study treatment duration per patient: 24 weeks study&#xD;
           duration per patient: 26 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c level for patients with addition of glulisine at week 12</measure>
    <time_frame>between week 12 and week 24 (end of treatment period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c level &lt; 7%</measure>
    <time_frame>at week 24 (end of treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c level &lt; 7% and no symptomatic nocturnal hypoglycemia event</measure>
    <time_frame>at week 24 (end of treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>at week 0, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Self Monitoring of Blood Glucose</measure>
    <time_frame>at week 0, week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dose of insulin glargine</measure>
    <time_frame>at week 24 (end of treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dose of insulin glulisine</measure>
    <time_frame>at week 24 (end of treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic / diastolic blood pressure, heart rate, weight change</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)</measure>
    <time_frame>from week 0 (from baseline) to week 24 (end of treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Intensive insulin regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c &lt;7% at week 12 (end of treatment period 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime</description>
    <arm_group_label>Intensive insulin regimen</arm_group_label>
    <arm_group_label>insulin regimen</arm_group_label>
    <other_name>Lantus SoloStar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal</description>
    <arm_group_label>Intensive insulin regimen</arm_group_label>
    <other_name>Apidra SoloStar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  in the run-in period:&#xD;
&#xD;
               1. Uncontrolled Type 2 diabetes mellitus defined as HbA1c level between 7,5% and 10%&#xD;
                  assessed over the past 6 months&#xD;
&#xD;
               2. Male or female patients from 18-75 years old inclusive&#xD;
&#xD;
               3. Body Mass Index (BMI) between 25 and 40 kg/m2&#xD;
&#xD;
               4. Currently treated with a basal insulin (NPH, insulin zinc or insulin detemir),&#xD;
                  plus at least 1g metformin daily, and other Oral Glucose Lowering Drug (OGLD) if&#xD;
                  any for at least 3 months&#xD;
&#xD;
               5. Signed Informed consent obtained prior to any study procedures&#xD;
&#xD;
          -  in the treatment period:&#xD;
&#xD;
               1. HbA1c level between 7,5% and 10% assessed between week -2 and week 0&#xD;
&#xD;
               2. Serum creatinine &lt;= 135 µmol/L in men and &lt;= 110 µmol/L in women&#xD;
&#xD;
               3. Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) &lt;= 3 times&#xD;
                  the upper limit of normal&#xD;
&#xD;
               4. Negative pregnancy test for women of childbearing potential&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Type 1 diabetes mellitus&#xD;
&#xD;
          2. Active proliferative diabetic retinopathy, defined as the application of&#xD;
             photocoagulation or surgery performed within 6 months before study entry or any other&#xD;
             unstable (rapidly progressing) retinopathy that may require photocoagulation or&#xD;
             surgery during the study (confirmed by an optic fundus performed over the past 2&#xD;
             years)&#xD;
&#xD;
          3. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major&#xD;
             disease making implementation of the protocol or interpretation of the study results&#xD;
             difficult&#xD;
&#xD;
          4. History of impaired hepatic function defined as Alanine aminotransferase (ALT) and/or&#xD;
             Aspartate aminotransferase (AST) greater than three times the upper limit of normal&#xD;
&#xD;
          5. History of impaired renal function defined as serum creatinine &gt;135 µmol/l in men and&#xD;
             &gt; 110 µmol/l in women&#xD;
&#xD;
          6. History of drug or alcohol abuse&#xD;
&#xD;
          7. Type 2 Diabetes Mellitus (T2DM) patients treated exclusively with OGLDs&#xD;
&#xD;
          8. T2DM patients treated with an insulin other than basal insulin (Premix, rapid insulin,&#xD;
             fast-acting insulin analogue)&#xD;
&#xD;
          9. Previous treatment with insulin glulisine&#xD;
&#xD;
         10. Concomitant treatment with thiazolidinediones, exenatide or pramlintide&#xD;
&#xD;
         11. Treatment with systemic corticosteroids within 3 months prior to study entry&#xD;
&#xD;
         12. Treatment with any investigational product within 2 months prior to study entry&#xD;
&#xD;
         13. History of hypersensitivity to the study drugs or to drugs with a similar chemical&#xD;
             structure&#xD;
&#xD;
         14. Presence of mental condition that, in the opinion of the investigator, indicates that&#xD;
             participation in the study is not in the best interest of the patient&#xD;
&#xD;
         15. Presence of geographic or social conditions that would restrict or limit the patient&#xD;
             participation for the duration of the study&#xD;
&#xD;
         16. Pregnant or breast feeding women&#xD;
&#xD;
         17. Women of childbearing potential not protected by effective contraceptive method of&#xD;
             birth control&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Dubaï</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Peru</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>August 29, 2012</last_update_submitted>
  <last_update_submitted_qc>August 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

